All In Biotech

Drug Trial Radar · NCT06404086

RECOVER-SLEEP: Platform Protocol

RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 830 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

830

Actual

Start

Jul 31, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

Conditions

  • Long COVID
  • Long COVID-19
  • Hypersomnia
  • Sleep Disturbance

Interventions

  • ModafinilDrug

    Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose. Study drug administration will total 10 weeks.

  • Modafinil PlaceboDrug

    The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment. Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.

  • SolriamfetolDrug

    The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness. Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.

  • Solriamfetol PlaceboDrug

    The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal. Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.

  • MelatoninDrug

    Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.

  • Melantonin PlaceboDrug

    Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.

  • Tailored lighting (TL) ActiveDevice

    TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

  • Tailored lighting (TL) PlaceboDevice

    TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of participants enrolled in each AppendixTime frame: 12 months

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center Phoenix

    Phoenix, Arizona

  • University of Arizona Banner Medical Center

    Tucson, Arizona

  • The Southern Arizona VA Health Care System

    Tucson, Arizona

  • Stanford University

    Palo Alto, California

  • University of California San Francisco General Hospital

    San Francisco, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Denver Health and Hospital Authority

    Denver, Colorado

  • Howard University Hospital

    Washington D.C., District of Columbia

  • University of Florida College of Medicine Jacksonville

    Jacksonville, Florida

  • Lakeland Regional Medical Center

    Lakeland, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • Morehouse School of Medicine

    Atlanta, Georgia

  • Emory University

    Atlanta, Georgia

  • Atlanta VA Medical Center

    Decatur, Georgia

  • Emory Hope Clinic

    Decatur, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Cook County Health Specialty Care Center

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Illinois at Chicago

    Chicago, Illinois

  • NorthShore Medical Group

    Evanston, Illinois

  • Saint Francis Medical Center

    Peoria, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Jadestone Clinical Research, LLC

    Silver Spring, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr.

    Boston, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • Rutgers University - Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • East Carolina University

    Greenville, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • University Hospitals of Cleveland Medical Center

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Southwest Family Medicine Associates

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.